These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 21171894

  • 21. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide.
    Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F.
    Thromb Haemost; 2013 Aug; 110(2):283-94. PubMed ID: 23765180
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Phospholipid regulates the activation of factor X by tissue factor/factor VIIa (TF/VIIa) via substrate and product interactions.
    Hathcock JJ, Rusinova E, Gentry RD, Andree H, Nemerson Y.
    Biochemistry; 2005 Jun 07; 44(22):8187-97. PubMed ID: 15924438
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Validation of apixaban anti-factor Xa assay and impact of body weight.
    Wasan SM, Feland N, Grant R, Aston CE.
    Thromb Res; 2019 Oct 07; 182():51-55. PubMed ID: 31450008
    [Abstract] [Full Text] [Related]

  • 27. Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor.
    Franssen J, Salemink I, Willems GM, Wun TC, Hemker HC, Lindhout T.
    Biochem J; 1997 Apr 01; 323 ( Pt 1)(Pt 1):33-7. PubMed ID: 9173898
    [Abstract] [Full Text] [Related]

  • 28. Apixaban, an oral, direct inhibitor of activated Factor Xa.
    Shantsila E, Lip GY.
    Curr Opin Investig Drugs; 2008 Sep 01; 9(9):1020-33. PubMed ID: 18729009
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
    Morell J, Sullivan B, Khalabuda M, McBride BF.
    J Clin Pharmacol; 2010 Sep 01; 50(9):986-1000. PubMed ID: 20124518
    [Abstract] [Full Text] [Related]

  • 32. Protein S binds to and inhibits factor Xa.
    Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH.
    Proc Natl Acad Sci U S A; 1994 Mar 29; 91(7):2728-32. PubMed ID: 8146182
    [Abstract] [Full Text] [Related]

  • 33. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.
    He K, Luettgen JM, Zhang D, He B, Grace JE, Xin B, Pinto DJ, Wong PC, Knabb RM, Lam PY, Wexler RR, Grossman SJ.
    Eur J Drug Metab Pharmacokinet; 2011 Sep 29; 36(3):129-39. PubMed ID: 21461793
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Anti-Xa activity in apixaban overdose: a case report.
    Barton J, Wong A, Graudins A.
    Clin Toxicol (Phila); 2016 Nov 29; 54(9):871-873. PubMed ID: 27436437
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.
    Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, Song Y, Pursley J, Boyd RA, Frost C.
    J Clin Pharmacol; 2016 May 29; 56(5):628-36. PubMed ID: 26331581
    [Abstract] [Full Text] [Related]

  • 37. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor.
    Wong PC, Pinto DJ, Zhang D.
    J Thromb Thrombolysis; 2011 May 29; 31(4):478-92. PubMed ID: 21318583
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.